Nikoloudis, A.; Strassl, I.; Binder, M.; Stiefel, O.; Wipplinger, D.; Milanov, R.; Aichinger, C.; Kaynak, E.; Machherndl-Spandl, S.; Buxhofer-Ausch, V.;
et al. Comparison of Benefits and Risks Associated with Anti-T-Lymphocyte Globulin (ATLG) Serotherapy in Methotrexate (MTX)- versus Mycophenolate Mofetil (MMF)-Based Hematopoietic Stem Cell Transplantation. Transplantology 2023, 4, 22-37.
https://doi.org/10.3390/transplantology4010005
AMA Style
Nikoloudis A, Strassl I, Binder M, Stiefel O, Wipplinger D, Milanov R, Aichinger C, Kaynak E, Machherndl-Spandl S, Buxhofer-Ausch V,
et al. Comparison of Benefits and Risks Associated with Anti-T-Lymphocyte Globulin (ATLG) Serotherapy in Methotrexate (MTX)- versus Mycophenolate Mofetil (MMF)-Based Hematopoietic Stem Cell Transplantation. Transplantology. 2023; 4(1):22-37.
https://doi.org/10.3390/transplantology4010005
Chicago/Turabian Style
Nikoloudis, Alexander, Irene Strassl, Michaela Binder, Olga Stiefel, Dagmar Wipplinger, Robert Milanov, Christoph Aichinger, Emine Kaynak, Sigrid Machherndl-Spandl, Veronika Buxhofer-Ausch,
and et al. 2023. "Comparison of Benefits and Risks Associated with Anti-T-Lymphocyte Globulin (ATLG) Serotherapy in Methotrexate (MTX)- versus Mycophenolate Mofetil (MMF)-Based Hematopoietic Stem Cell Transplantation" Transplantology 4, no. 1: 22-37.
https://doi.org/10.3390/transplantology4010005
APA Style
Nikoloudis, A., Strassl, I., Binder, M., Stiefel, O., Wipplinger, D., Milanov, R., Aichinger, C., Kaynak, E., Machherndl-Spandl, S., Buxhofer-Ausch, V., Böhm, A., Petzer, A., Weltermann, A., Wolf, D., Nachbaur, D., & Clausen, J.
(2023). Comparison of Benefits and Risks Associated with Anti-T-Lymphocyte Globulin (ATLG) Serotherapy in Methotrexate (MTX)- versus Mycophenolate Mofetil (MMF)-Based Hematopoietic Stem Cell Transplantation. Transplantology, 4(1), 22-37.
https://doi.org/10.3390/transplantology4010005
